Dyne Therapeutics (NASDAQ:DYN) Shares Up 5.2%

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s share price shot up 5.2% on Friday . The stock traded as high as $34.27 and last traded at $34.06. 9,555 shares changed hands during trading, a decline of 99% from the average session volume of 1,722,095 shares. The stock had previously closed at $32.39.

Analysts Set New Price Targets

Several brokerages have recently weighed in on DYN. HC Wainwright boosted their target price on Dyne Therapeutics from $36.00 to $48.00 and gave the stock a “buy” rating in a report on Monday, May 20th. Oppenheimer restated an “outperform” rating and set a $47.00 target price on shares of Dyne Therapeutics in a report on Monday, May 6th. Morgan Stanley began coverage on Dyne Therapeutics in a report on Tuesday, April 30th. They set an “overweight” rating and a $40.00 target price on the stock. Stifel Nicolaus lifted their price target on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Finally, Piper Sandler lifted their price target on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $40.78.

Dyne Therapeutics Stock Up 8.1 %

The company has a market cap of $3.06 billion, a PE ratio of -8.82 and a beta of 1.06. The business has a 50-day simple moving average of $28.98 and a 200-day simple moving average of $23.78.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.81) EPS for the quarter, hitting the consensus estimate of ($0.81). As a group, equities research analysts predict that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Insiders Place Their Bets

In other Dyne Therapeutics news, COO Susanna Gatti High sold 40,000 shares of the business’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $33.36, for a total value of $1,334,400.00. Following the completion of the transaction, the chief operating officer now owns 148,792 shares in the company, valued at $4,963,701.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider Oxana Beskrovnaya sold 2,705 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $28.27, for a total transaction of $76,470.35. Following the completion of the transaction, the insider now owns 149,647 shares in the company, valued at $4,230,520.69. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Susanna Gatti High sold 40,000 shares of the business’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $33.36, for a total transaction of $1,334,400.00. Following the transaction, the chief operating officer now owns 148,792 shares of the company’s stock, valued at approximately $4,963,701.12. The disclosure for this sale can be found here. Insiders sold a total of 162,183 shares of company stock worth $5,098,485 over the last 90 days. Corporate insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Wetzel Investment Advisors Inc. acquired a new position in shares of Dyne Therapeutics during the first quarter worth $28,000. Ameritas Investment Partners Inc. boosted its stake in Dyne Therapeutics by 28.0% in the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after acquiring an additional 1,291 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Dyne Therapeutics by 355.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock valued at $94,000 after acquiring an additional 5,541 shares in the last quarter. EntryPoint Capital LLC acquired a new position in Dyne Therapeutics in the first quarter valued at $214,000. Finally, SG Americas Securities LLC acquired a new position in Dyne Therapeutics in the fourth quarter valued at $172,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.